MedTrace Logo

A Clinical Trial to Evaluate the Safety and Pharmacokinetic

NCT03475719 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2018-03-23

No results posted yet for this study

Summary

A phase 1 clinical trail to evaluate the safety and pharmacokinetic characteristic after administration of fixed-dose combination or loose combination of HUG186 in healthy adult male or menopausal female volunteers

Conditions

  • Osteoporosis, Postmenopausal

Interventions

DRUG

HUG186-B and HUG186-D

Bazedoxifene acetate 22.6mg, Cholecalciferol 8.0mg(=800IU)

DRUG

HUG186

Combination of Bazedoxifene acetate 22.6mg and Cholecalciferol 8.0mg(=800IU)

Sponsors & Collaborators

  • Huons Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-11
Primary Completion
2018-02-11
Completion
2018-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03475719 on ClinicalTrials.gov